Abstract:Background Diffuse intrinsic pontine glioma (DIPG) is an incurable pediatric brain tumor. Mutations in the H3 histone tail (H3.1/3.3-K27M) are a feature of DIPG, potentially rendering them therapeutically sensitive to small-molecule inhibition of chromatin modifiers. Pharmacological inhibition of lysine specific demethylase-1 (LSD1) shows promise in pediatric cancers such as Ewing’s sarcoma, but has not been investigated in DIPG, which was the aim of our study.Methods Patient-derived DIPG cell lines and pediatric high-grade glioma (pHGG) datasets were used to evaluate effects of several LSD1 inhibitors on selective cytotoxicity and immune gene expression. Immune cell cytotoxicity was assessed in DIPG cells treated with LSD1 inhibitors and informatics platforms were used to determine immune infiltration of pHGG and impact on survival.Results Selective cytotoxicity and an immunogenic gene signature was established in DIPG lines using several clinically-relevant LSD1 inhibitors. Pediatric high-grade glioma patient sequencing data demonstrated survival benefit using this LSD1-dependent gene signature. On-target binding of catalytic LSD1 inhibitors was confirmed in DIPG and pre-treatment of DIPG with these inhibitors increased lysis by natural killer (NK) cells. CIBERSORT analysis of patient data confirmed NK infiltration is beneficial to patient survival while CD8 T-cells are negatively prognostic. Catalytic LSD1 inhibitors are non-perturbing to NK cells while scaffolding LSD1 inhibitors are toxic to NK cells and do not induce the gene signature in DIPG cells.Conclusions LSD1 inhibition using catalytic inhibitors are both selectively cytotoxic and promote an immune gene signature that is associated with NK cell killing, representing a therapeutic opportunity for pHGG.Key points 1. LSD1 inhibition using several clinically relevant compounds is selectively cytotoxic in DIPG.2. An LSD1-controlled gene signature predicts survival in pediatric high-grade glioma patients.3. LSD1 inhibition enhances NK cell cytotoxicity against DIPG with correlative genetic biomarkers.Importance of the study This is the first study to evaluate inhibition of LSD1 in a uniformly lethal type of pediatric brain tumor: DIPG. We demonstrate selective cytotoxicity of several clinically relevant compounds against patient derived DIPG cells, and identify an immune gene signature that is upregulated in DIPG cells by catalytic inhibitors of LSD1. This immune gene signature is predictive of prognosis in pHGG, consistent with the rationale of promoting this signature through LSD1 inhibition. NK cell killing of DIPG is enhanced by LSD1 inhibition, providing functional confirmation of this gene signature, and represents the first report of LSD1 inhibition promoting NK cell cytotoxicity of cancer cells. Given the poor prognosis of pHGGs and lack of effective treatments, our results suggest use of LSD1 inhibition as a single agent or in combination with NK cell therapy may be a safe and efficacious strategy.

Pharmacologic Inhibition Of Lysine-Specific Demethylase 1 As A Therapeutic And Immune-Sensitization Strategy In Pediatric High-Grade Glioma

Pharmacologic Inhibition of Lysine Specific Demethylase-1 (LSD1) As a Therapeutic and Immune-Sensitization Strategy in Diffuse Intrinsic Pontine Glioma (DIPG)

EXTH-67. PHARMACOLOGIC INHIBITION OF LYSINE SPECIFIC DEMETHYLASE-1 (LSD1) AS AN ADJUVANT IMMUNE-SENSITIZATION STRATEGY IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)

Tmic-36. Evaluating Pharmacological Inhibition Of Lsd1 In Models Of Diffuse Midline Glioma And Effects On Immune Microenvironment Signaling

Novel pharmacologic inhibition of lysine-specific demethylase 1 as a potential therapeutic for glioblastoma

412 Synergistic Targeting of Lysine-specific demethylase 1 (LSD1) and MAPK Signaling: A Mechanism-Guided Therapeutic Approach for Glioblastoma (GBM)

Comparison of pharmacological inhibitors of lysine-specific demethylase 1 in glioblastoma stem cells reveals inhibitor-specific efficacy profiles

DIPG-14. EVALUATING THERAPEUTIC VULNERABILITIES IN DIPG TUMORS USING HIGH-THROUGHPUT SCREENING

OS06.3A LSD1-directed therapy curtails glioblastoma tumorigenicity by limiting the adaptation of tumor initiating cells to stressful environments

DIPG-39. NOVEL PROTEOMIC ANALYSIS REVEALS EPIGENETIC THERAPEUTIC TARGETS IN PEDIATRIC GLIOMA

Dual Targeting of Histone Deacetylases and MYC as Potential Treatment Strategy for H3-K27M Pediatric Gliomas

EPIG-02DYNAMIC EPIGENETIC MODULATION OF GLIOBLASTOMA TUMORIGENICITY BY INHIBITION OF LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1)

Csig-26. Targeting Epigenetic Dysregulation And Adaptive Resistance Mechanisms In Dipg/Dmg

DIPG-14. INTEGRATED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) NEXT-GENERATION SEQUENCING REVEALS EPIGENETIC DYSREGULATION OF GENE EXPRESSION AND BROMODOMAIN INHIBITION AS A NOVEL THERAPEUTIC TARGET

H3.3-G34R Mutation-Mediated Epigenetic Reprogramming Leads to Enhanced Efficacy of Immune Stimulatory Gene Therapy in Pediatric High-Grade Gliomas

Csig-13. Targeting Genetic Dependencies Exposes Diffuse Midline Glioma Cell Of Origin Vulnerabilities

Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma

DIPG-21. EVALUATING THERAPEUTIC VULNERABILITIES IN DIPG USING AURORA KINASE INHIBITOR AS A NOVEL THERAPY

H3.3 K27M Depletion Increases Differentiation and Extends Latency of Diffuse Intrinsic Pontine Glioma Growth in Vivo

Antitumor Activity Of Novel Pyrazole-Based Small Molecular Inhibitors Of The Stat3 Pathway In Patient Derived High Grade Glioma Cells

Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma